Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press74210.17650/2222-1468-2022-12-1-107-113REVIEWSОБЗОРНЫЕ СТАТЬИModern strategies for the treatment of patients with kidney cancer of brain metastases: literature reviewСовременные стратегии лечения пациентов с метастазами рака почки в головной мозг: обзор литературыhttps://orcid.org/0000-0002-6792-967XRoshchinaK. E.РощинаК. Е.
Russian Federation

Kristina Evgenievna Roshchina

Moscow

Кристина Евгеньевна Рощина

г. Москва

Roshhina93@list.ruhttps://orcid.org/0000-0002-4160-9598BekyashevA. Kh.БекяшевА. Х.
Russian Federation

A. Kh. Bekyashev

Moscow

А. Х. Бекяшев

г. Москва

https://orcid.org/0000-0002-4218-9652NaskhletashviliD. R.НасхлеташвилиД. Р.
Russian Federation

D. R. Naskhletashvili

Moscow

Д. Р. Насхлеташвили

г. Москва

https://orcid.org/0000-0003-0747-9037OsinovI. K.ОсиновИ. К.
Russian Federation

I. K. Osinov

Moscow

И. К. Осинов

г. Москва

https://orcid.org/0000-0001-6433-1202SavateevA. N.СаватеевА. Н.
Russian Federation

A. N. Savateev

Moscow

А. Н. Саватеев

г. Москва

https://orcid.org/0000-0001-5261-9014KhalafyanD. A.ХалафянД. А.
Russian Federation

D. A. Khalafyan

Moscow

Д. А. Халафян

г. Москва

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииCenter “Gamma Knife” of N. N. Burdenko National Medical Research Center of NeurosurgeryЦентр «Гамма-нож» ФГАУ «Национальный медицинский исследовательский центр нейрохирургии им. акад. Н. Н. Бурденко» Минздрава России190420221211071131904202219042022Copyright ©; 2022, Roshchina K.E., Bekyashev A.K., Naskhletashvili D.R., Osinov I.K., Savateev A.N., Khalafyan D.A.Copyright ©; 2022, Рощина К.Е., Бекяшев А.Х., Насхлеташвили Д.Р., Осинов И.К., Саватеев А.Н., Халафян Д.А.2022Roshchina K.E., Bekyashev A.K., Naskhletashvili D.R., Osinov I.K., Savateev A.N., Khalafyan D.A.Рощина К.Е., Бекяшев А.Х., Насхлеташвили Д.Р., Осинов И.К., Саватеев А.Н., Халафян Д.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/742

According to the literature, metastatic brain damage in kidney cancer occurs in 6.5 % of patients. The introduction of new techniques associated with the use of targeted drugs, immune checkpoint inhibitors and innovative radiation therapy techniques can significantly increase patient survival. Effective drug therapy and local control of brain metastases are of paramount importance for predicting overall survival and quality of life for patients. This literature review summarizes the scientific literature data on the use of local and systemic methods of treatment in patients with metastases of kidney cancer to the brain.

Метастатическое поражение головного мозга при раке почки, по данным литературы, встречается у 6,5 % пациентов. Внедрение новых методик, применяемых с применением таргетных препаратов, ингибиторов контроля точек иммунитета и методов лучевой терапии, позволяет значительно увеличить выживаемость пациентов. Эффективная лекарственная терапия и локальный контроль метастазов в головной мозг имеют первостепенное значение для прогноза общей выживаемости и качества жизни больных. В этом обзоре обобщены данные научной литературы об операциях и системных методах лечения пациентов с метастазами рака почки в головной мозг.

kidney cancerbrain metastaseslocal treatmenttargeted therapyimmune checkpoint inhibitorsрак почкиметастазы в головной мозглокальное лечениетаргетная терапияингибиторы контрольных точек иммунитетаSchouten L., Rutten J., Huveneers H. et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94(10): 2698–705. DOI: 10.1002/cncr.10541.Sun M., Velasco G., Brastianos P., Aizer A. et al. The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 2019;5(3):474–81. DOI: 10.1016/j.euf.2017.12.007.Golanov A.V., Banov S.M., Ilyalov S.R. et al. Modern approaches to radiation treatment of metastatic brain damage. Zlokachestvennye opuholi = Malignant Tumors 2014;(3):137–40. (In Russ.). DOI: 10.18027/2224-5057-2014-3-137-140.Голанов А.В., Банов С.М., Ильялов С.Р. и др. Современные подходы к лучевому лечению метастатического поражения головного мозга. Злокачественные опухоли 2014;3:137–40. DOI: 10.18027/2224-5057-2014-3-137-140.Heng D., Choueiri T., Rini B. et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014;25(1):149–54. DOI: 10.1093/annonc/mdt492.Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23(4):973–80. DOI: 10.1093/annonc/mdr362.Sun M., Velasco D.G., Brastianos P. et al. The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a populationbased cohort. Eur Urol Focus 2019;5(3):474–81. DOI: 10.1016/j.euf.2017.12.007.Zhuang W., Li Y., Chen P. et al. Do renal cell carcinoma patients with brain metastases still need nephrectomy? Int Urol Nephrol 2019;51(6):941–9. DOI: 10.1007/s11255-019-02139-9.Ke Z., Chen S., Chen Y. et al. Risk factors for brain metastases in patients with renal cell carcinoma. BioMed Res Int 2020;2020:6836234. DOI: 10.1155/2020/6836234.Tsivian M., Moreira D., Caso Jorge R. et al. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol 2011;29(15):2027–31. DOI: 10.1200/JCO.2010.30.9484.Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur Urol 2019;75(5):799–810. DOI: 10.1016/j.eururo.2019.02.011.Ward R., Tanaka H., Campbell S. et al. 2017 AUA renal mass and localized renal cancer guidelines: imaging implications. Radio Graphics 2018;38(7):2021–33. DOI: 10.1148/rg.2018180127.Sperduto P., Kased N., Roberge D. et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30(4):419–25. DOI: 10.1200/JCO.2011.38.0527.Gaspar L., Scott C., Rotman M. et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiation Oncol Biol Phys 1997;37(4):745–51. DOI: 10.1016/s0360-3016(96)00619-0.Aleshin V.A., Bekyashev A.Kh., Belov D.M. et al. Individualization of treatment of patients with cerebral metastases of malignant tumors. The Tunes Predictive Scale. Zlokachestvennye opuholi = Malignant Tumors 2017;7(4):48–52. (In Russ.). DOI: 10.18027/2224-5057-2017-7-4-48-52.Алешин В.А., Бекяшев А.Х., Белов Д.М. и др. Индивидуализация лечения пациентов с церебральными метастазами злокачественных опухолей. Прогностическая шкала TuNS. Злокачественные опухоли 2017;7(4):48–52. DOI: 10.18027/2224-5057-2017-7-4-48-52.Ali M., Hirshman B., Wilson B. et al. Improving the prognostic value of diseasespecific graded prognostic assessment model for renal cell carcinoma by incorporation of cumulative intracranial tumor volume. World Neurosurg 2017;108:151–6. DOI: 10.1016/j.wneu.2017.07.109.Ali Z., Rottey S., Barthelemy P. et al. Brain metastasis and renal cell carcinoma: prognostic scores assessment in the era of targeted therapies. Anticancer Res 2019;39(6):2993–3002. DOI: 10.21873/anticanres.13431.Vickers M., Al-Harbi H., Choueiri T. et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013;11(3):311–5. DOI: 10.1016/j.clgc.2013.04.012.Banov S.M., Galanov A.V., Ilyalov S.R. et al. Results of radiosurgical and drug treatment of patients with brain metastases. Opuholi golovy i shei = Head and Neck Tumors 2017;7(3):19–30. (In Russ.). DOI: 10.17650/2222-14682017-7-3-19-30.Банов С.М., Голанов А.В., Ильялов С.Р. и др. Результаты радиохирургического и лекарственного лечения пациентов с метастазами в головной мозг. Опухоли головы и шеи 2017;7(3):19–30. DOI: 10.17650/2222-14682017-7-3-19-30.Noordijk E., Vecht С., Haaxma-rekhe H. et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29(4):711–6. DOI: 10.1016/0360-3016(94)90558-4.Vetlova E.R., Barinov S.M., Galanov A.V. Modern strategy of combination of surgical and radiation treatment in patients with brain metastases. Zhurnal “Voprosy nejrohirurgii” im. akad. N.N. Burdenko = Journal “Questions of Neurosurgery” named after akad. N.N. Burdenko. 2017;81(6):108–15. (In Russ.). DOI: 10.17116/neiro2017816108-115.Ветлова Е.Р., Банов С.М., Голанов А.В. Современная стратегия комбинации хирургического и лучевого лечения у пациентов с метастазами в головном мозге. Журнал «Вопросы нейрохирургии» им. акад. Н.Н. Бурденко 2017;81(6):108–15. DOI: 10.17116/neiro2017816108-115.Hara W., Tran P., Li G. et al. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery 2009;64 (2 Suppl):A26–32. DOI: 10.1227/01.NEU.0000339118.55334.EA.Sheehan J., Sun M., Kondziolka D. et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: longterm outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 2003;98(2):342–9. DOI: 10.3171/jns.2003.98.2.0342.Soltys S., Adler J., Lipani J. et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008;70(1):187–93. DOI: 10.1016/j.ijrobp.2007.06.068.Chang E., Selek U., Hassenbusch S. et al. Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005;56(5):936–45. DOI: 10.1227/01.NEU.0000158324.20757.AC.Verma J., Jonasch E., Allen P. et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 2013;36(6):620–4. DOI: 10.1097/COC.0b013e31825d59db.Ippen F., Mahadevan A., Wong E. et al. Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J Oncol 2015;2015:636918. DOI: 10.1155/2015/636918.Bekyashev A.Kh., Golanov A.V., Dreval O.N. et al. Kidney cancer with brain metastases. Prognostic factors and treatment results. Opuholi golovy i shei = Head and Neck Tumors 2016;6(3):53–60. (In Russ.). DOI: 10.17650/2222-1468-2016-6-353-60.Бекяшев А.Х., Голанов А.В., Древаль О.Н. и др. Рак почки с метастазами в головной мозг. Факторы прогноза и результаты лечения. Опухоли головы и шеи 2016;6(3):53–60. DOI: 10.17650/2222-1468-2016-6-353-60.Molenaar R., Wiggenraad R., Kanter A. et al. Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg 2009;23(2):170–8. DOI: 10.1080/02688690902755613.Vogelbaum M., Angelov L., Lee S. et al. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 2006:104(6):907–12. DOI: 10.3171/jns.2006.104.6.907.Yamamoto M., Kawabe T., Sato Y. et al. Stereotactic radiosurgery for patients with multiple brain metastases: a casematched study comparing treatment results for patients with 2–9 versus 10 or more tumors. J Neurosurg 2014;121:16–25. DOI: 10.3171/2014.8.GKS141421.Dirk R., Stefan H., Volker R. Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. Anticancer Res 2015;35(1):333–6.Aleshin V.A., Karakhan V.B., Bekyashev A.Kh., Belov D.M. Lung cancer metastases to the brain – the role of the neurosurgical stage of treatment. Opuholi golovy i shei = Head and Neck Tumors 2016;6(2):42–9. (In Russ.). DOI: 10.17650/2222-14682016-6-2-42-49.Алешин В.А., Карахан В.Б., Бекяшев А.Х., Белов Д.М. Метастазы рака легкого в головной мозг – роль нейрохирургического этапа лечения. Опухоли головы и шеи 2016;6(2):42–9. DOI: 10.17650/2222-14682016-6-2-42-49.Belov D.M., Karakhan V.B., Bekyashev A.Kh., Aleshin V.A. Surgical stage in the complex treatment of patients with cerebral metastases of breast cancer. Zlokachestvennye opuholi = Malignant Tumors 2014;3:110–5. (In Russ.). DOI: 10.18027/2224-5057-2014-3110-115.Белов Д.М., Карахан В.Б., Бекяшев А.Х., Алешин В.А. Хирургический этап в комплексном лечении пациенток с церебральными метастазами рака молочной железы. Злокачественные опухоли 2014;3:110–5. DOI: 10.18027/2224-5057-2014-3110-115.Soffietti R., Ahluwalia M., Lin N. et al. Management of brain metastases according to molecular subtypes. Nat Rev Neurol 2020;16(10):557–74. DOI: 10.1038/s41582-020-0391-x.Pardridge W. Drug and gene delivery to the brain. Neuron 2002;36(4):555–8. DOI: 10.1016/s0896-6273(02)01054-1.Hu S., Chen Z., Franke R., Orwick S. et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15(19):6062–9. DOI: 10.1158/1078-0432.CCR09-0048.Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse. Ann Oncol 2011;22(8):1812–23. DOI: 10.1093/annonc/mdq651.Henderson C., Bukowski R., Stadler W. et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol 2007;25(18_suppl.):15506. DOI: 10.1200/jco.2007.25.18_suppl.15506.Jäger D., Ma J., Mardiak J. et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer 2015;13(2):156– 64.е1. DOI: 10.1016/j.clgc.2014.07.007.Gore M., Hariharan S., Porta C. et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;117(3):501–9. DOI: 10.1002/cncr.25452.Sternberg C., Calabrò F., Bracarda S. et al. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expandedaccess trial. Oncology 2015;88(5):273–80. DOI: 10.1159/000369256.Jacobs C., Kim D., Straka C. et al. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. J Clin Oncol 2013;31(7):e114–7. DOI: 10.1200/JCO.2012.46.0501.Matrana M., Duran C., Shetty A. et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49(15):3169–75. DOI: 10.1016/j.ejca.2013.06.003.Matveev V.B., Olshanskaya A.S., Volkova M.I. Kabozantinib: from research to real clinical practice. Onkourologiya = Oncourology 2019;15(3):28–41. In Russ.). DOI: 10.17650/1726-97762019-15-3-28-41.Матвеев В.Б., Ольшанская А.С., Волкова М.И. Кабозантиниб: от исследований к реальной клинической практике. Онкоурология 2019;15(3):28–41. DOI: 10.17650/1726-97762019-15-3-28-41.Négrier S., Moriceau G., Attignon V. et al. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. J Med Case Rep 2018;12(1):351. DOI: 10.1186/s13256-018-1875-9.Hirsch L., Chanza N., Farah S. et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 2021;7(12):1815–23. DOI: 10.1001/jamaoncol.2021.4544.Hirsch L., Chanza N., Farah S. et al. Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): an international multicenter study. J Clin Oncol 2021;39(6_suppl.):310. DOI: 10.1200/JCO.2021.39.6_suppl.310.Kattan J., Rassy E., Assi T. et al. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. Crit Rev Oncol Hematol 2018;130:60–9. DOI: 10.1016/j.critrevonc.2018.08.001.Berghoff A., Venur V., Preusser M., Ahluwaliaeng M. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book 2016;35:e116–22. DOI: 10.1200/EDBK_100005.Flippot R., Dalban C., Laguerre B. et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol 2019;37(23);2008–16. DOI: 10.1200/JCO.18.02218.Emamekhoo H., Olsen M., Carthon B. et al. Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: interim analysis of CheckMate 920. J Clin Oncol 2019;37(15_suppl.):4517. DOI: 10.1002/cncr.34016.